Guangzhou, China
RiboBio is a Chinese biotechnology company, established in 2004, that specializes in RNA-based products and services. Recognized as the top revenue-generating company in this sector in China by the 2017 Frost & Sullivan Report, RiboBio has over 15 years of experience in synthesizing and manufacturing oligonucleotides. With a portfolio exceeding 1,000,000 oligonucleotides, the company offers diverse, high-quality reagents including siRNA, miRNA mimics and inhibitors, LncRNA probes, and smart silencing kits for RNA-related research.
RiboBio stands out through its exclusive "one-stop" RNA-based outsourcing services, catering to various customer needs, spanning from drug discovery and development to manufacturing. This includes comprehensive CRO and CDMO services, encompassing both GMP and non-GMP oligo-based APIs. To learn more about their CDMO and CRO capabilities, visit their link here: cdmocmo.ribobio.com/en/
The latest notable financial injection into RiboBio was a Venture Round investment on 06 July 2017, with CXVC as the investor.
With its strong foothold in the realms of biotechnology, health care, life sciences, manufacturing, and pharmaceuticals, RiboBio continues to solidify its position as a leading innovator in the RNA-based product and service landscape. #RiboBio
